The government aims to grow the pharmaceutical industry by about four times to $200 billion by 2030, Arunish Chawla, secretary, department of pharmaceuticals, said. The sector should be able to achieve the target through the help of industrial...
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) approved Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)...
SciBase Holding AB (SciBase), a leading provider of augmented intelligence-based skin diseases solutions, signed a partnership agreement with the Skin and Cancer Institute to trial Nevisense in many of their California sites. The Skin and...
Astellas Pharma Inc. has agreed to buy Propella Therapeutics, Inc. for roughly $175 million. The acquisition is planned to take place during Astellas' fiscal year 2023, which will expire on March 31, 2024. PRL-02 (abiraterone decanoate), a...
voke Pharma, Inc announced that the US Patent and Trademark Office (USPTO) issued US Patent No. 11,813,231 titled "Nasal Formulations of Metoclopramide" pertaining to the company's commercially available and FDA-approved nasal formulation of...
Imfinzi (durvalumab), manufactured by AstraZeneca, has been licensed in China for the first-line treatment of adults with locally advanced or metastatic biliary tract cancer (BTC) in conjunction with chemotherapy (gemcitabine and cisplatin)...
Almirall S.A. launched a drug discovery collaboration with the goal of developing and commercializing AI-designed therapies for chronic and severe dermatological conditions. The collaboration combines Absci's Integrated Drug Creation platform with...
Gland Pharma said that it has got permission from the US Food and Drug Administration to manufacture a generic blood pressure medication. According to a regulatory filing, the Hyderabad-based business has acquired provisional clearance from the US...
Autifony Therapeutics Limited (Autifony), a company that is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain diseases, announced a $770.5 million exclusive global licensing agreement with...
Yesafili, a biosimilar of aflibercept, has been given marketing permission by the UK Medicines and Healthcare products Regulatory Agency (UK MHRA), according to Biocon Biologics, a subsidiary of Biocon. In September, Yesafili, received marketing...
, CDSCO.jpg)
.jpg)